Piscopo Leandra, Zampella Emilia, Pellegrino Sara, Volpe Fabio, Nappi Carmela, Gaudieri Valeria, Fonti Rosa, Vecchio Silvana Del, Cuocolo Alberto, Klain Michele
Department of Advanced Biomedical Sciences, University of Naples, Federico II, 80131 Naples, Italy.
Cancers (Basel). 2023 Jul 4;15(13):3483. doi: 10.3390/cancers15133483.
Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) constitute an ideal target for radiolabeled somatostatin analogs. The theragnostic approach is able to combine diagnosis and therapy by the identification of a molecular target that can be diagnosed and treated with the same radiolabeled compound. During the last years, advances in functional imaging with the introduction of somatostatin analogs and peptide receptor radionuclide therapy, have improved the diagnosis and treatment of GEP-NENs. Moreover, PET/CT imaging with F-FDG represents a complementary tool for prognostic evaluation of patients with GEP-NENs. In the field of personalized medicine, the theragnostic approach has emerged as a promising tool in diagnosis and management of patients with GEP-NENs. The aim of this review is to summarize the current evidence on diagnosis and management of patients with GEP-NENs, focusing on the theragnostic approach.
胃肠胰神经内分泌肿瘤（GEP-NENs）是放射性标记生长抑素类似物的理想靶点。诊疗一体化方法能够通过识别一个可用相同放射性标记化合物进行诊断和治疗的分子靶点，将诊断与治疗结合起来。在过去几年中，随着生长抑素类似物的引入以及肽受体放射性核素治疗，功能成像技术取得了进展，改善了GEP-NENs的诊断和治疗。此外，F-FDG PET/CT成像对于GEP-NENs患者的预后评估是一种补充工具。在精准医学领域，诊疗一体化方法已成为GEP-NENs患者诊断和管理中有前景的工具。本综述的目的是总结GEP-NENs患者诊断和管理的当前证据，重点关注诊疗一体化方法。
